Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Sovaldi (sofosbuvir) + ribavirin in adolescents and children with chronic HCV genotype 2 or 3
2014-002283-32Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir in chronic hepatitis C (CHC) and hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoints: AUCtau of GS-331007 and Steady-state pharmacokinetics of sofosbuvir and GS-331007. Started Jul 2014; status: completed.
02
Drugs
sofosbuvir
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2014-002283-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002283-32.